Expression-analysis of the human endogenous retrovirus HERV-K in human astrocytic tumors

BMC Research Notes

Carsten Hagemann¹  Ralf-Ingo Ernestus¹  Mario Löhr¹  Thomas Linsenmann¹  Giles Hamilton Vince⁴  Ulrike Kämmerer²  Joachim Denner³  Miriam Wiesner¹  Almuth Friederike Kessler¹ 

[1] Tumorbiology Laboratory, Department of Neurosurgery, University of Würzburg, Josef-Schneider-Str. 11, Würzburg D-97080, Germany;Department of Obstetrics and Gynaecology, University of Würzburg, Josef-Schneider-Str. 4, Würzburg D-97080, Germany;Robert Koch Institute, Nordufer 20, Berlin D-13353, Germany;Current address: Klinikum Klagenfurt am Wörthersee, Department of Neurosurgery, Feschnigstr. 11, Klagenfurt 9020, Austria

关键词: PCR analysis;    Glioblastoma cell line;    Expression;    Astrocytic tumor;    Glioblastoma multiforme;    HERV-K;    Human endogenous retrovirus;   

Others  :  1134227
DOI  :  10.1186/1756-0500-7-159

 received in 2013-10-31, accepted in 2014-03-14,  发布年份 2014

【 摘 要 】

Background

The human endogenous retrovirus K (HERV-K) has been acquired by the genome of human ancestors million years ago. It is the most complete of the HERVs with transcriptionally active gag, pol and env genes. Splice variants of env, which are rec, 1.5 kb transcript and Np9 have been suggested to be tumorigenic. Transcripts of HERV-K have been detected in a multitude of human cancers. However, no such reports are available concerning glioblastomas (GBM), the most common malignant brain tumor in adults. Patients have a limited prognosis of 14.6 months in median, despite standard treatment. Therefore, we elucidated whether HERV-K transcripts could be detected in these tumors and serve as new molecular target for treatment.

Findings

We analyzed human GBM cell lines, tissue samples from patients and primary cell cultures of different passages for HERV-K full length mRNA and env, rec and 1.5 kb transcripts. While the GBM cell lines U138, U251, U343 and GaMG displayed weak and U87 strong expression of the full length HERV-K, the splice products could not be detected, despite a weak expression of env mRNA in U87 cells. Very few tissue samples from patients showed weak expression of env mRNA, but none of the rec or 1.5 kb transcripts. Primary cells expressed the 1.5 kb transcript weakly in early passages, but lost HERV-K expression with extended culture time.

Conclusions

These data suggest that HERV-K splice products do not play a role in human malignant gliomas and therefore, are not suitable as targets for new therapy regimen.

【 授权许可】

   
2014 Kessler et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Li WH, Gu Z, Wang H, Nekrutenko A: Evolutionary analyses of the human genome. Nature 2001, 409:847-849.
• [2]Cegolon L, Salata C, Weiderpass E, Vineis P, Palù G, Mastrangelo G: Human endogenous retroviruses and cancer prevention: evidence and prospects. BMC Cancer 2013, 13:4. BioMed Central Full Text
• [3]Löwer R, Löwer J, Kurth R: The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 1996, 93:5177-5184.
• [4]Tristem M: Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project databese. J Virol 2000, 74:3715-3730.
• [5]Löwer R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Löwer J, Kurth R: Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci USA 1993, 90:4480-4484.
• [6]Boeke JD, Stoye JP: Retrotransposons, endogenous retroviruses, and the evolution of retroelements. In Retroviruses. Edited by Coffin JM, Hughes SH, Varmus HE. Cold Spring harbour (NY: Cold Spring Harbour Laboratory Press; 1997.
• [7]Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, Fodinger D, Seppele H, Schanab O, Magin-Lachmann C, Lower R, Jansen B, Pehamberger H, Wolff K: An endogenous retrovirus derived from human melanoma cells. Cancer Res 2003, 63:8735-8741.
• [8]Bannert N, Kurth R: Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14572-14579.
• [9]Mayer J: Status of HERV in human cells: expression and coding capacity of human proviruses. Dev Biol (Basel) 2001, 106:439-441. discussion 465–475
• [10]Büscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J: Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005, 65:4172-4180.
• [11]Khodosevich K, Lebedev Y, Sverdlov E: Endogenous retroviruses and human evolution. Comp Funct Genomics 2002, 3:494-498.
• [12]Löwer R, Tonjes RR, Korbmacher C, Kurth R, Löwer J: Identification of a Rev-related protein by analysis of spliced transcripts of the human endogenous retroviruses HTDV/HERV-K. J Virol 1995, 69:141-149.
• [13]Boese A, Sauter M, Galli U, Best B, Herbst H, Mayer J, Kremmer E, Roemer K, Mueller-Lantzsch N: Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. Oncogene 2000, 19:4328-4336.
• [14]Galli UM, Sauter M, Lecher B, Maurer S, Herbst H, Roemer K, Mueller-Lantzsch N: Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors. Oncogene 2005, 24:3223-3228.
• [15]Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N: Physical and functional interactions of human endogeneous retrovirus proteins Np9 and rec with the promyelocytic leukemia zink finger protein. J Virol 2007, 85:5607-5616.
• [16]Armbruester V, Sauter M, Krautkraemer E, Meese E, Kleiman A, Best B, Roemer K, Mueller-Lantzsch N: A novel gene from the human endogenous retrovirus K expressed in transformed cells. Clin Cancer Res 1800–1807, 2002:8.
• [17]Chen T, Meng Z, Gan Y, Wang X, Xu F, Gu Y, Xu X, Tang J, Zhou H, Zhang X, Gan X, Van Ness C, Xu G, Huang L, Zhang X, Fang Y, Wu J, Zheng S, Jin J, Huang W, Xu R: The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch 1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia 2013, 27:1469-1478.
• [18]Voisset C, Weiss RA, Griffiths DJ: Human RNA “Rumor” viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev 2008, 72:157-196.
• [19]Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF, Shaw DR, Strong TV: Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res 2001, 7:1553-1560.
• [20]Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, Hahn S, Löwer R, Wolff K, Bergmann M, Muster T, Mayer B, Pehamberger H: Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res 2006, 66:1658-1663.
• [21]Hahn S, Ugurel S, Hanschmann KM, Strobel H, Tondera C, Schadendorf D, Löwer J, Löwer R: Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses 2008, 24:717-723.
• [22]Wang-Johanning F, Radvanyi L, Rycaj K, Plummer JB, Yan P, Jagannadha Sastry K, Piyathilake C, Hunt KK, Johanning GL: Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res 2008, 68:5869-5877.
• [23]Kraus B, Fischer K, Büchner SM, Wels WS, Löwer R, Sliva K, Schnierle BS: Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system. Plos One 2013, 8:e72756.
• [24]Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, Garza JG, Shen J, Lin K, Yan P, Glynn SA, Dorsey TH, Hunt KK, Ambs S, Johanning GL: Immunotherapeutic potential of anti-human endogenous retrovirus-k envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012, 104:189-210.
• [25]Reifenberger G, Collins VP: Pathology and molecular genetics of astrocytic gliomas. J Mol Med 2004, 82:656-670.
• [26]Demuth T, Berens ME: Molecular mechanisms of glioma cell migration and invasion. J Neur-Oncol 2004, 70:217-228.
• [27]Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899.
• [28]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and radiotherapy Groups, National Cancer Institute of canada Clinical trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
• [29]Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH: Expression of matrix metalloproteinase MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res 2008, 60:40-49.
• [30]Wagner S, Czub S, Greif M, Vince GH, Süss N, Kerkau S, Rieckmann P, Roggendorf W, Roosen K, Tonn JC: Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 1999, 82:12-16.
• [31]Hagemann C, Mayer C, Stojic J, Eicker S, Gerngras S, Kühnel S, Roosen K, Vince GH: High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J Neurosci Methods 2006, 156:194-202.
• [32]Said HM, Hagemann C, Stojic J, Schoemig B, Vince GH, Flentje M, Roosen K, Vordermark D: GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol 2007, 8:55. BioMed Central Full Text
• [33]Said HM, Polat B, Hagemann C, Anacker J, Flentje M, Vordermark D: Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in vitro. BMC Res Notes 2009, 2:8. BioMed Central Full Text
• [34]Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, Patel R, Kämmerer U, Vordermark D, Roosen K, Vince GH: Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. Oncol Rep 2008, 20:301-308.
• [35]Hagemann C, Anacker J, Haas S, Riesner D, Schömig B, Ernestus R-I, Vince GH: Comparative expression pattern of matrix-metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res Notes 2010, 3:293. BioMed Central Full Text
• [36]Tan Q, Lui PP, Rui YF: Effect of in vitro passaging on the stem cell related properties of tendon-derived stem cells – implications in tissue engineering. Stem Cells Dev 2012, 21:790-800.
• [37]Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS, the HCMV and Glioma Symposium: Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 2012, 14:246-255.